Press Releases

September 27, 2023

HepQuant Paticipates in Media Pitch Day

Fitzsimmons Innovation Community hosted its first Media Pitch Day. Check out the summary:
June 13, 2023

HepQuant Announces Additions to the Executive Leadership Team to Drive Commercialization

Kelly R. Pitts, PhD, Chief Operating Officer; Carrie Mulherin, MBA, Chief Commercial Officer; Shailesh Chavan, MD, Chief Medical Officer; Paige Nardi, MBA VP Market Access Denver, CO – June 13, 2023 – HepQuant, LLC, a leader transforming the management of liver diseases, announces key additions to its executive leadership team….

April 14, 2023

Kelly R. Pitts, Ph.D., Appointed Chief Operating Officer

Medical Diagnostics Industry Veteran with Biotech and Biopharma Experience Will Guide Operations DENVER (Apr. 14, 2023) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced its has chosen Kelly R. Pitts, Ph.D., as its new Chief…

January 23, 2023

HepQuant Lab Moves to New Location Within Fitzsimons Innovation Community Campus

The HepQuant Lab has moved a short distance within the Fitzsimons Innovation Community Campus to Bioscience 1, located at 12635 E. Montview Blvd., Suite 175, Aurora, CO 80045. The new lab space is adjacent to our previous location where we’ve been for the past five years, according to HepQuant Chief…

August 24, 2022

HepQuant Lab Meets COLA – CLIA Quality Standards

DENVER (Aug. 24, 2022) — HepQuant, LLC,  a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that the HepQuant laboratory has achieved COLA accreditation for laboratory quality assurance. COLA is a third-party accreditation organization that ensures labs comply with federal…

May 24, 2022

Preliminary data from the HepQuant SHUNT-V Pivotal study presented at DDW® 2022

SAN DIEGO (May 24, 2022) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced preliminary data from the SHUNT-V Pivotal study in oral and poster presentations at Digestive Disease Week® (DDW) 2022 in San Diego….

May 10, 2022

Chris Jensen Joins Business Advisory Board

Former J.P. Morgan Investment Banker Brings Mid-Market Capital-Raising Experience to Board  DENVER (May 10, 2022) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that former J.P. Morgan Investment Banker Chris Jensen has…